Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

Bosentan and Rifampin Interactions Modulate Influx Transporter and Cytochrome P450 Expression and Activities in Primary Human Hepatocytes

  • Han, Kyoung-Moon (Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) ;
  • Ahn, Sun-Young (Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) ;
  • Seo, Hyewon (Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) ;
  • Yun, Jaesuk (Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) ;
  • Cha, Hye Jin (Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) ;
  • Shin, Ji-Soon (Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) ;
  • Kim, Young-Hoon (Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) ;
  • Kim, Hyungsoo (Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) ;
  • Park, Hye-kyung (Pharmacological Research Division, Toxicological and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) ;
  • Lee, Yong-Moon (College of Pharmacy, Chungbuk National University)
  • Received : 2016.07.12
  • Accepted : 2016.10.27
  • Published : 2017.05.01
Download PDF
⟨ Previous Next ⟩

Abstract

The incidence of polypharmacy-which can result in drug-drug interactions-has increased in recent years. Drug-metabolizing enzymes and drug transporters are important polypharmacy modulators. In this study, the effects of bosentan and rifampin on the expression and activities of organic anion-transporting peptide (OATP) and cytochrome P450 (CYP450) 2C9 and CYP3A4 were investigated in vitro. HEK293 cells and primary human hepatocytes overexpressing the target genes were treated with bosentan and various concentrations of rifampin, which decreased the uptake activities of OATP transporters in a dose-dependent manner. In primary human hepatocytes, CYP2C9 and CYP3A4 gene expression and activities decreased upon treatment with $20{\mu}M$ $bosentan+200{\mu}M$ rifampin. Rifampin also reduced gene expression of OATP1B1, OATP1B3, and OATP2B1 transporter, and inhibited bosentan influx in human hepatocytes at increasing concentrations. These results confirm rifampin- and bosentan-induced interactions between OATP transporters and CYP450.

Keywords

References

  1. Campbell, E. A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A. and Darst, S. A. (2001) Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell 104, 901-912. https://doi.org/10.1016/S0092-8674(01)00286-0
  2. Dingemanse, J. and van Giersbergen, P. L. (2004) Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin. Pharmacokinet. 43, 1089-1115. https://doi.org/10.2165/00003088-200443150-00003
  3. Fujiwara, R., Takenaka, S., Hashimoto, M., Narawa, T. and Itoh, T. (2014) Expression of human solute carrier family transporters in skin: possible contributor to drug-induced skin disorders. Sci. Rep. 4, 5251.
  4. Guo, L., Dial, S., Shi, L., Branham, W., Liu, J., Fang, J. L., Green, B., Deng, H., Kaput, J. and Ning, B. (2011) Similarities and differences in the expression of drug-metabolizing enzymes between human hepatic cell lines and primary human hepatocytes. Drug Metab. Dispos. 39, 528-538. https://doi.org/10.1124/dmd.110.035873
  5. Han, J. Y., Ahn, S. Y., Yoo, J. H., Nam, S. Y., Hong, J. T. and Oh, K. W. (2015) Alleviation of kainic acid-induced brain barrier dysfunction by 4-o-methylhonokiol in in vitro and in vivo models. Biomed Res. Int. 2015, 893163.
  6. Jeong, H. U., Kwon, M., Lee, Y., Yoo, J. S., Shin, D. H., Song, I. S. and Lee, H. S. (2015) Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide. Drug Des. Devel. Ther. 9, 643-653.
  7. Kalliokoski, A. and Niemi, M. (2009) Impact of OATP transporters on pharmacokinetics. British journal of pharmacology 158, 693-705. https://doi.org/10.1111/j.1476-5381.2009.00430.x
  8. Lin, J. H. and Lu, A. Y. (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Br. J. Pharmacol. 35, 361-390.
  9. Menochet, K., Kenworthy, K. E., Houston, J. B. and Galetin, A. (2012) Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes. Drug Metab. Dispos. 40, 1744-1756. https://doi.org/10.1124/dmd.112.046193
  10. Ofotokun, I. (2005) Sex differences in the pharmacologic effects of antiretroviral drugs: potential roles of drug transporters and phase 1 and 2 metabolizing enzymes. Top. HIV Med. 13, 79-83.
  11. Perez, G., Tabares, B., Jover, R., Gomez-Lechon, M. J. and Castell, J. V. (2003) Semi-automatic quantitative RT-PCR to measure CYP induction by drugs in human hepatocytes. Toxicol. In Vitro 17, 643-649. https://doi.org/10.1016/S0887-2333(03)00109-7
  12. Sasayama, S., Kunieda, T., Tomoike, H., Matsuzaki, M., Shirato, K., Kuriyama, T., Izumi, T., Origasa, H., Giersbergen, P. L., Dingemanse, J. and Tanaka, S. (2005) Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension. Circ. J. 69, 131-137. https://doi.org/10.1253/circj.69.131
  13. Seki, S., Kobayashi, M., Itagaki, S., Hirano, T. and Iseki, K. (2009) Contribution of organic anion transporting polypeptide OATP2B1 to amiodarone accumulation in lung epithelial cells. Biochim. Biophys. Acta 1788, 911-917. https://doi.org/10.1016/j.bbamem.2009.03.003
  14. Treiber, A., Schneiter, R., Hausler, S. and Stieger, B. (2007) Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab. Dispos. 35, 1400-1407. https://doi.org/10.1124/dmd.106.013615
  15. van Giersbergen, P. L., Treiber, A., Schneiter, R., Dietrich, H. and Dingemanse, J. (2007) Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin. Pharmacol. Ther. 81, 414-419. https://doi.org/10.1038/sj.clpt.6100075
  16. Wienkers, L. C. and Heath, T. G. (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug Discov. 4, 825-833. https://doi.org/10.1038/nrd1851
  17. Williamson, B., Dooley, K. E., Zhang, Y., Back, D. J. and Owen, A. (2013) Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. Antimicrob. Agents Chemother. 57, 6366-6369. https://doi.org/10.1128/AAC.01124-13
  18. Zhang, Z. H., Tang, J. H., Zhan, Z. L., Zhang, X. L., Wu, H. H. and Hou, Y. N. (2012) Cellular toxicity of isoniazid together with rifampicin and the metabolites of isoniazid on QSG-7701 hepatocytes. Asian Pac. J. Trop. Med. 5, 306-309. https://doi.org/10.1016/S1995-7645(12)60044-3

Cited by

  1. Organic Anion-Transporting Polypeptide Genes Are Not Induced by the Pregnane X Receptor Activator Rifampin: Studies in Hepatocytes In Vitro and in Monkeys In Vivo vol.47, pp.12, 2017, https://doi.org/10.1124/dmd.119.088922
  2. Induction of Human Intestinal and Hepatic Organic Anion Transporting Polypeptides: Where Is the Evidence for Its Relevance in Drug-Drug Interactions? vol.48, pp.3, 2017, https://doi.org/10.1124/dmd.119.089615
  3. Classification of drugs for evaluating drug interaction in drug development and clinical management vol.41, pp.None, 2017, https://doi.org/10.1016/j.dmpk.2021.100414